Triomics raises $22M Series B for oncology-specific AI platform
Original: Triomics nabs $22M to bring oncology-specific AI to cancer centers
Why This Matters
Addresses critical oncology workflow inefficiencies as patient survival increases
Triomics, founded in 2021, secured $22 million Series B funding led by Battery Ventures to expand its AI platform that helps oncologists automate clinical trial matching, patient summaries, and administrative tasks at cancer centers.
The startup builds AI tools specifically trained on oncology data to help healthcare staff manage dense, multi-year medical records that can span thousands of pages. The platform generates verifiable patient summaries within existing clinical tools and automates tumor report submissions to government registries. Major clients include Memorial Sloan Kettering and Yale Cancer Center. Co-founder Sarim Khan reported the company expanded its enterprise customer base fourfold over the past year, driving a 10-fold increase in annualized recurring revenue. The Series B follows a $15 million Series A in mid-2024, with participation from Nexus Venture Partners, Lightspeed, and Y Combinator.